Cost-Efficacy in the Study of Comparative Treatments for Retinal Vein Occlusion 2—Should We Consider Step Therapy for Retinal Vein Occlusion?
- 1 June 2023
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 141 (6) , 561-563
Abstract
Retinal vein occlusions (RVOs) cause substantial vision loss and visual impairment in the working-age population, and disease burden is growing with an estimated 28.06 million people affected worldwide in 2015.1 Restoring and maintaining vision for RVO typically is reliant on frequent costly treatments and close surveillance, with anti–vascular endothelial growth factor (VEGF) agents often used as first-line treatments for the sequelae of RVO including macular edema and neovascularization. This large treatment and surveillance burden coupled with the cost of treatment options motivates cost-effectiveness analyses such as that performed by Kymes et al2 evaluating repackaged (compounded) bevacizumab compared with aflibercept for the treatment of macular edema associated with central RVO (CRVO) or hemiretinal RVO (HRVO).Keywords
This publication has 7 references indexed in Scilit:
- Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 TrialJAMA Ophthalmology, 2023
- Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO StudyPharmacoEconomics, 2021
- Cost-Utility of Anti–Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein OcclusionOphthalmology Retina, 2020
- Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein OcclusionOphthalmology Retina, 2020
- Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein OcclusionJAMA Ophthalmology, 2019
- Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factorsJournal of Global Health, 2019
- Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein OcclusionJAMA, 2017